Clinical Trials Browser

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT06561685 2026-02-10

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

340 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT05208944 2026-01-20

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Recruiting

227 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT07284186 2026-01-16

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

155 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

300 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Recruiting

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06605404 2025-08-14

Pan-tumor MRD Study

Recruiting

1,350 enrolled

DermatologicGastrointestinalThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma

NCT03093116 2025-07-10

TRIDENT-1

Phase 1/2 Recruiting

500 enrolled 2 FDA

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04401059 2023-12-27

SELECT-2

Phase 4 Recruiting

744 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung